These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26090082)

  • 1. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson's Disease Dementia.
    Oh YS; Kim JS; Lee PH
    J Mov Disord; 2015 May; 8(2):98-102. PubMed ID: 26090082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
    Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
    Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
    Aarsland D; Hutchinson M; Larsen JP
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease.
    Aarsland D; Cummings JL; Larsen JP
    Int J Geriatr Psychiatry; 2001 Feb; 16(2):184-91. PubMed ID: 11241724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress.
    Aarsland D; Brønnick K; Ehrt U; De Deyn PP; Tekin S; Emre M; Cummings JL
    J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):36-42. PubMed ID: 16820421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
    Wesnes K
    Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson's disease dementia.
    Lee WJ; Tsai CF; Gauthier S; Wang SJ; Fuh JL
    Int Psychogeriatr; 2012 Dec; 24(12):1980-7. PubMed ID: 22835209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment.
    Simon-Gozalbo A; Rodriguez-Blazquez C; Forjaz MJ; Martinez-Martin P
    Front Neurol; 2020; 11():731. PubMed ID: 32849203
    [No Abstract]   [Full Text] [Related]  

  • 12. Rivastigmine and Parkinson dementia complex.
    Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
    Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
    Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between cognitive dysfunction and behavioural symptoms in Nigerian patients with Parkinson's disease no dementia.
    Ojagbemi A
    J Parkinsons Dis; 2013 Jan; 3(3):293-300. PubMed ID: 23963316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.
    Emre M; Cummings JL; Lane RM
    J Alzheimers Dis; 2007 Jul; 11(4):509-19. PubMed ID: 17656830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine for the treatment of dementia associated with Parkinson's disease.
    Reingold JL; Morgan JC; Sethi KD
    Neuropsychiatr Dis Treat; 2007 Dec; 3(6):775-83. PubMed ID: 19300613
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.